Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (115)
ARTG (99)
Prescription medicine registration (52)
Australian Public Assessment Report (AusPAR) (31)
Designation or determination (31)
Prescription medicine evaluation (9)
Prescription medicine decision summary (2)

Date

2024 (25)
2023 (33)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (12)
2013 (16)
2012 (6)
2011 (4)
2009 (10)
2008 (6)
2007 (6)
2006 (10)
2005 (1)
2003 (1)
2002 (7)
2000 (1)
1998 (1)
1997 (5)
1996 (1)
1993 (1)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

339 result(s) found, displaying 201 to 210

BELSOMRA suvorexant 20mg tablet blister pack (207712)

16 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for BELSOMRA suvorexant 20mg tablet blister pack.
BELSOMRA suvorexant 15mg tablet blister pack (207709)

16 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for BELSOMRA suvorexant 15mg tablet blister pack.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

5 March 2019

Prescription medicine registration

Active ingredients: pembrolizumab.
NITRO-DUR 10 glyceryl trinitrate 80mg (10mg/24h) transdermal drug delivery system, sachet Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
NITRO-DUR 15 glyceryl trinitrate 120mg (15mg/24h) Transdermal drug delivery system, sachet Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
NITRO-DUR 5 glyceryl trinitrate 40mg (5mg/24h) transdermal drug delivery system, sachet Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
NITRO-DUR 7.5 glyceryl trinitrate 60mg (7.5mg/24h) transdermal drug delivery system, sachet Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
CRIXIVAN indinavir 200mg (as sulfate) capsule bottle Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
CRIXIVAN indinavir 400mg (as sulfate) capsule bottle Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
CUBICIN (Merck Sharp & Dohme (Australia) Pty Ltd)

22 January 2019

Prescription medicine registration

Active ingredients: daptomycin.

Pages

First page
Previous page
…
Page 17
Page 18
Page 19
Page 20
Current page 21
Page 22
Page 23
Page 24
Page 25
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.